N- (tris((beta- galactopyranosyloxy)methyl)methyl)- N(alpha)- (4- (5- cholesten- 3 beta-yloxy)succinyl)glycinamide

RN & RR given from first source; structure given in first source

Also Known As:

N-(tris((beta-galactopyranosyloxy)methyl)methyl)-N(alpha)-(4-(5-cholesten-3 beta-yloxy)succinyl)glycinamide, 3H-labeled; TGMAC; tris-Gal-Chol

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Aguilar-Calvo, Patricia: 1 article (10/2019)
2.	Birling, Marie-Christine: 1 article (10/2019)
3.	Comoy, Emmanuel E: 1 article (10/2019)
4.	Deslys, Jean-Philippe: 1 article (10/2019)
5.	Espinosa, Juan Carlos: 1 article (10/2019)
6.	Marin-Moreno, Alba: 1 article (10/2019)
7.	Pitarch, José Luis: 1 article (10/2019)
8.	Torres, Juan María: 1 article (10/2019)

1.	Infections 10/30/2019 - "Interestingly, TgMac were more susceptible to classical-BSE strain infection than Hu-Tg340. "